Bright Minds Biosciences Inc.DRUGNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank67
3Y CAGR-19.8%
5Y CAGR-18.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-19.8%/yr
Quarterly compound
5Y CAGR
-18.2%/yr
Consistent
Percentile
P67
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 44.00% |
| Q3 2025 | 27.78% |
| Q2 2025 | -12.46% |
| Q1 2025 | 25.00% |
| Q4 2024 | 54.11% |
| Q3 2024 | 9.47% |
| Q2 2024 | -11.81% |
| Q1 2024 | -9.37% |
| Q4 2023 | -12.63% |
| Q3 2023 | 20.73% |
| Q2 2023 | -32.40% |
| Q1 2023 | -29.47% |
| Q4 2022 | 85.14% |
| Q3 2022 | -28.58% |
| Q2 2022 | -5.82% |
| Q1 2022 | -26.90% |
| Q4 2021 | 17.63% |
| Q3 2021 | -16.02% |
| Q2 2021 | 98.05% |
| Q1 2021 | 112.72% |
| Q4 2020 | 120.19% |
| Q3 2020 | 409.09% |
| Q2 2020 | 11014.20% |
| Q1 2020 | 141.43% |
| Q4 2019 | 0.00% |